Skip to main content

Table 2 Relationship between immune cell subset infiltration and clinicopathologic features of pure ductal carcinoma in situ

From: Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast

Clinicopathologic characteristics

CD4+ TIL

CD8+ TIL

FOXP3+ TIL

PD-L1+ IC

No. of TILs

p value

No. of TILs

p value

No. of TILs

p value

Frequency (%)

p value

Age (year)

 

0.577

 

0.218

 

0.815

 

0.792

 < 50

19.7 (4.2–50.7)

 

12.7 (6.2–26.7)

 

0.0 (0.0–1.0)

 

21/132 (15.9)

 

 ≥ 50

19.0 (3.8–44.5)

 

12.0 (4.2–22.2)

 

0.0 (0.0–1.0)

 

13/89 (14.6)

 

DCIS extent (cm)

 

0.950

 

0.799

 

0.811

 

0.929

 < 2.5

19.7 (5.0–47.5)

 

12.7 (5.3–24.2)

 

0.0 (0.0–1.0)

 

21/138 (15.2)

 

 ≥ 2.5

17.3 (3.7–49.7)

 

11.3 (5.0–26.2)

 

0.0 (0.0–1.0)

 

13/83 (15.7)

 

Nuclear grade

 

< 0.001

 

0.001

 

< 0.001

 

< 0.001

 Low to intermediate

12.7 (2.0–37.5)

 

10.0 (4.7–18.2)

 

0.0 (0.0–0.0)

 

11/142 (7.7)

 

 High

25.3 (11.5–77.8)

 

15.7 (8.0–35.8)

 

0.0 (0.0–3.0)

 

23/79 (29.1)

 

Comedo-type necrosis

 

0.004

 

0.002

 

0.008

 

< 0.001

 Absent

16.0 (3.4–42.0)

 

10.7 (5.3–20.1)

 

0.0 (0.0–0.0)

 

17/174 (9.8)

 

 Present

31.5 (13.6–86.1)

 

22.5 (8.5–41.5)

 

0.0 (0.0–5.0)

 

17/47 (36.2)

 

ER

 

0.026

 

0.025

 

0.004

 

0.043

 Negative

34.0 (13.6–82.4)

 

22.5 (7.6–48.8)

 

0.5 (0.0–5.0)

 

8/27 (29.6)

 

 Positive

17.0 (3.7–43.5)

 

11.8 (5.3–22.0)

 

0.0 (0.0–0.0)

 

26/194 (13.4)

 

PR

 

0.027

 

< 0.001

 

0.002

 

0.019

 Negative

34.0 (12.1–76.3)

 

24.2 (10.2–48.9)

 

0.0 (0.0–4.9)

 

11/40 (27.5)

 

 Positive

16.0 (3.7–42.0)

 

10.7 (4.7–19.5)

 

0.0 (0.0–0.0)

 

23/181 (12.7)

 

HER2

 

0.354

 

0.010

 

0.004

 

0.059

 Negative

17.3 (3.8–44.5)

 

12.0 (5.2–22.0)

 

0.0 (0.0–0.0)

 

25/189 (13.2)

 

 Positive

28.7 (6.8–73.2)

 

22.0 (7.3–48.5)

 

0.0 (0.0–5.2)

 

9/32 (28.1)

 

Ki-67 index

 

0.001

 

0.009

 

< 0.001

 

< 0.001

 < 10%

15.8 (3.4–40.1)

 

11.0 (4.9–20.2)

 

0.0 (0.0–0.0)

 

17/164 (10.4)

 

 ≥ 10%

34.8 (9.3–96.2)

 

16.2 (8.3–36.3)

 

0.0 (0.0–5.0)

 

17/57 (29.8)

 

P53

 

0.001

 

0.041

 

0.016

 

0.092

 Negative

16.3 (3.7–40.4)

 

11.5 (4.9–22.4)

 

0.0 (0.0–0.1)

 

26/192 (13.5)

 

 Positive

49.0 (18.8–80.8)

 

17.0 (9.4–31.2)

 

0.0 (0.0–3.0)

 

8/29 (27.6)

 
  1. For CD4+, CD8+, and FOXP3+ TILs, p values were calculated by the Mann-Whitney U test, and data are presented as median (interquartile range)
  2. For PD-L1+ IC, p values were calculated by chi-square or Fisher’s exact test, and data are presented as frequency (%)
  3. TIL tumor-infiltrating lymphocyte, IC immune cell, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us